On 4 March 2025, AbbVie announced that Skyrizi® (risankizumab) is now available in Canada for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
The UC indication was approved by Health Canada in October 2024. It is the fourth indication approved for Skyrizi® in Canada following approvals for moderately to severely active Crohn’s disease (October 2022), active psoriatic arthritis (March 2022) and moderate to severe plaque psoriasis (March 2019).
Skyrizi® was approved for treatment of UC by the European Commission in July 2024, and by the US FDA in June 2024.